VX-809 25mg 25mg | Purity Not Available
Adooq Bioscience
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF).
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVX-765 is a novel Caspase-1 inhibitor,which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18.
More Information Supplier PageVorinostat is an inhibitor of HDACs, inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors.
More Information Supplier Page